Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-β-cyclodextrin complex

Pharmazie

Volumn 67, Issue 1, 2012, Pages 46-53

  Lv, Hui Xia ^a   Zhang, Zhen Hai ^b   Hui Jiang, ^c   Waddad, Ayman Y ^a   Zhou, Jian Ping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Jiangsu Province Academy of Traditional Chinese Medicine   (China)

^c Qilu Pharmacutical Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ATORVASTATIN; ATORVASTATIN HYDROXYPROPYL BETA CYCLODEXTRIN COMPLEX; UNCLASSIFIED DRUG; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; EXCIPIENT; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR MODEL; NONHUMAN; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; TABLET COMPRESSION; TABLET DISINTEGRATION; TABLET HARDNESS; TASTE; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY POWDER DIFFRACTION; ALGORITHM; ANALYSIS OF VARIANCE; ANIMAL; BIOAVAILABILITY; CHEMICAL STRUCTURE; CHEMISTRY; DELAYED RELEASE FORMULATION; ELECTROCHEMISTRY; HARDNESS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SOLUBILITY; TABLET; X RAY DIFFRACTION;

ALGORITHMS; ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; ELECTROCHEMISTRY; EXCIPIENTS; HARDNESS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PYRROLES; RATS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TABLETS; X-RAY DIFFRACTION;

EID: 84858769378     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1082     Document Type: Article

References (16)

1. Ben Zirar S, Astie A, Muchow M, Gibaud S (2008) Comparison of nanosuspensions and hydroxypropyl-β-cyclodextrin complex of melarsoprol: Pharmacokinetics and tissue distribution in mice. Eur J Pharm Biopharm 70: 649-656.
2. Cabral Marques HM, Hadgraft J, Kellaway IW, Pugh WJ (1990) Studies of cyclodextrin inclusion complexes. Part 2. Molecular modeling and proton NMR evidence for the salbutamol-β-cyclodextrin complex. Int J Pharm 63: 267-274.
3. Crupi V, Ficarra R, Guardo M, Majolino D, Stancanelli R, Venuti V (2007) UV-vis and FTIR-ATR spectroscopic techniques to study the inclusion complexes of genistein withβ-cyclodextrins. J Pharm Biomed Anal 44: 110-117.
4. FDA (2008) Guidance for Industry Orally Disintegrating Tablet.
5. Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS (2008) Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Therap 30: 195-205.
6. Frömming KH, Szejtli J (1994) Cyclodextrin in Pharmacy; Kluwer Academic Publishers. Dordrecht.
7. Gould S, Scott RC (2005) 2-Hydroxypropyl beta cyclodextrin: a toxicological review. Food Chem Toxicol 43: 1451-1459.
8. Higuchi T, Connors KA (1965) Phase-solubility techniques. Adv Anal Chem Instr 4: 117-122.
9. Kappelle PJ, Dallinga-Thie GM, Dullaart RP (2010) Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets. Biochim Biophys Acta 1801: 89-94.
10. Khedr A (2007) Stability-indicating high-performance liquid chromatographic assay of atorvastatin with fluorescence detection. J AOAC Int 90: 1547-1553.
11. Kim MS, Jin SJ, Kim JS, Song HS, Neubert RH, Hwang SJ (2008) Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 69: 454-465.
12. Lipitor (2006) http://www.fda.gov/ohrms/DOCKETS/ac/06/briefing/2006- 4254b_16_02_KP%20Atorvastatin%20Label%20FDA%208-7-06.pdf.
13. Loftsson T, Brewster ME (1996) Pharmaceutical applications of cyclodextrins. 1: Drug solubilization and stabilization. J Pharm Sci 85: 1017-1025.
14. Yaksh TL, Janq JD, Nishiuchi Y, Braun KP, Ro SG, Goodman M (1991). The utility of 2-hydroxypropyl beta cyclodextrin as a vehicle for the intracerebral and intrathecal administration of Drugs. Life Sci 48: 623-634.
15. Yang J, Wiley CJ, Godwin DA, Felton LA (2008) Influence of hydroxypropyl-β-cyclodextrin on transdermal penetration and photostability of avobenzone. Eur J Pharm Biopharm 69: 605-612.
16. Simons J (2003) The $10 Billion Pill Hold the fries, please. Lipitor, the cholesterol-lowering drug, has become the best selling pharmaceutical in history. Here's how Pfizer did it, Fortune magazine, January 20.